Samsung Bioepis, Teva sign global pact for up to six biosimilar candidates
Bitget2026/10/01 08:30- Samsung EPIS Holdings unit Samsung Bioepis signed a global license, development, and commercialization deal with Teva for up to six biosimilars.
- Samsung Bioepis to develop, file, and manufacture; Teva to commercialize in the US, Europe, Canada, with an option to add territories.
- Initial confirmed candidates include SB41 referencing AstraZeneca’s Fasenra, SB44 referencing Novartis’ Ilaris.
- Deal expands an existing partnership that already commercialized EPYSQLI in the US, with OPUVIZ added for Canada.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SEI Price Prediction: Can SEI Rally From $0.06 to $1?
Japanese life insurance companies plan to increase holdings of Japanese government bonds, and demand for super-long-term JGBs is expected to improve.
Japan Post Insurance announced plans to increase its purchases of yen-denominated bonds, while Daido Life Insurance has raised its target for domestic bond holdings, focusing mainly on corporate bonds. Meiji Yasuda Life Insurance plans to keep its holdings of Japanese government bonds largely unchanged but will swap low-yield bonds for higher-yield varieties. This week, the 20-year government bond auction recorded a historic high bid-to-cover ratio, and life insurance institutions have been net buyers of super-long-term Japanese government bonds for four consecutive months.
Crypto prices
More
